Chembio, OraSure Update On Efforts To Deliver Ebola POC Tests
This article was originally published in The Gray Sheet
Executive Summary
Chembio Diagnostics officials say its partnership with Integrated Biotherapeutics to combine IBT’s Ebola reagents with Chembio’s DPP technology for delivery of a simple-to-use, rapid test is expected to yield fruit soon, while OraSure says it will reach key milestones on its prospective Ebola test effort this year.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.